Navigation Links
Xencor, Inc. Announces Closing of Initial Public Offering
Date:12/6/2013

MONROVIA, Calif., Dec. 6, 2013 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the closing of its initial public offering of 14,639,500 shares of its common stock at an initial public offering price of $5.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,909,500 additional shares of common stock. Xencor's common stock is listed on The NASDAQ Global Market under the trading symbol "XNCR." All of the shares in the offering were offered by Xencor. Xencor estimates net proceeds from the offering to be approximately $72.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Credit Suisse Securities (USA) LLC and Leerink Swann LLC are acting as joint book-running managers of the offering. Wedbush PacGrow Life Sciences is acting as a co-manager for the offering.

A registration statement relating to the securities being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on December 2, 2013. The offering was made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by calling toll-free (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com; or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at Syndicate@Leerink.com, or by phone at (800) 808-7525.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology.  Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Concord Medical Announces the Closing of Acquisition of Its Shares by CEO and COO from Other Shareholders
3. Osseon Announces New Regional Sales Director
4. UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
5. EarlySense Announces Patient Rest Indicator for Better Patient Supervision at Night
6. Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder
7. Cyberonics Announces Expansion of Share Repurchase Program By An Additional One Million Shares
8. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
9. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders
10. Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
11. MiMedx Announces Next Steps After Discussions With The FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign ... for the Access to Contraception for Women Servicemembers and Dependents Act of 2017. ... (D-CA), will help to ensure that all members of the Armed Forces receive ...
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... UT (PRWEB) , ... April 28, 2017 , ... Beginning ... some of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ... be changing the formula in the following ways:, , Removal ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it ... 19 hours without sleep can compromise motor reaction time, which can increase the risk of ... is sharing the following tips from the NSF to help you sleep better and feel ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
Breaking Medicine News(10 mins):